Bristol Myers Squibb, shared by RayzeBio, on LinkedIn, adding:
“As demand for next-generation radiopharmaceutical therapies continues to grow, we’re investing more than $173 million to expand manufacturing capacity in the United States and strengthen the infrastructure needed to help bring these innovations to people living with cancer. Led by RayzeBio, this investment will support new jobs, expand our radiopharmaceutical manufacturing network, and help position Indiana as a growing hub for life sciences innovation.
Together, we’re advancing the capabilities needed to deliver the next generation of cancer treatments to patients.”
Quoting RayzeBio:
“We’re excited to expand our Indiana footprint with a planned $173 million investment that will create up to 100 new high quality jobs across Indianapolis and Whitestown by the end of 2029. The investment includes a new state-of-the-art facility in Whitestown that will complement our existing Indianapolis operations and strengthen the infrastructure needed to advance the next generation of radiopharmaceutical therapies.
We’re proud to deepen our commitment to Indiana’s growing life sciences ecosystem, invest in local talent, and help drive innovation that can make a difference for patients.”
Other articles about RayzeBio on OncoDaily.